Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

92616

registered interest
date	10/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hip Replacements
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many hip replacement operations were conducted in (a) Devon and Cornwall and (b) England in (i) 2013 and (ii) 2014.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	209295
answer	answer is ministerial correction date of answer 20/10/2014 answer text <p>In the following table, we have provided information concerning the number of finished consultant episodes (FCEs)<sup>1</sup> with a main or secondary procedure<sup>2</sup> of hip replacement<sup>3</sup> in Devon, Cornwall and Isles of Scilly Area Team of Treatment, and England.</p><p> </p><p> </p><p> </p><p>Data for 2013-14 is currently provisional and will be published once it has been validated.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Devon, Cornwall and Isles of Scilly Area Team of Treatment</p></td><td><p>England</p></td></tr><tr><td><p>2012-13</p></td><td><p>5,311</p></td><td><p>105,499</p></td></tr></tbody></table><p> </p><p>Activity in English NHS Hospitals and English NHS commissioned activity in the independent sector</p><p> </p><p><strong> </strong></p><p> </p><p><em>Notes:</em></p><p> </p><p>1. A finished consultant episode (FCE) is a continuous period of admitted patient care under one consultant within one healthcare provider. FCEs are counted against the year in which they end. Figures do not represent the number of different patients, as a person may have more than one episode of care within the same stay in hospital or in different stays in the same year.</p><p> </p><p>2. The number of episodes where the procedure (or intervention) was recorded in any of the 24 (12 from 2002-03 to 2006-07 and 4 prior to 2002-03) procedure fields in a Hospital Episode Statistics (HES) record. A record is only included once in each count, even if the procedure is recorded in more than one procedure field of the record. Note that more procedures are carried out than episodes with a main or secondary procedure.</p><p> </p><p>3. Coding used includes replacements, revisions and conversions of both hip replacements and hemiarthroplasty.</p><p> </p><p> </p><p> </p><p><em>Source:</em> Hospital Episode Statistics (HES), Health and Social Care Information Centre</p><p><strong><br> </strong></p> answering member constituency Battersea answering member printed Jane Ellison question first answered 20/10/2014 17:38:05 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

58513

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the changes in the level of access to prostate cancer treatments since 2010.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199302
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199303 199304 question first answered 10/06/2014 15:28:08 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

58515

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what treatments for prostate cancer are routinely funded by NHS England.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199303
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199302 199304 question first answered 10/06/2014 15:28:10 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

58516

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of outcomes for men with advanced prostate cancer.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199304
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199302 199303 question first answered 10/06/2014 15:28:11 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

49356

registered interest
date	30/04/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what his policy is on the licensing of e-cigarettes.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	197421
answer	answer is ministerial correction date of answer 06/05/2014 answer text <p /> <p /> <p>On 14 March 2014, European Union member states formally adopted the revised Tobacco Products Directive, including the provisions for regulation of electronic cigarettes. Article 18 of the Directive will subject electronic cigarettes to consumer products legislation, with specific additional regulatory requirements unless they fall under the definition of a medicinal product.</p><p> </p><p>The Medicines and Healthcare products Regulatory Agency is continuing to focus on regulating medicinal nicotine containing products, including electronic cigarettes, to enable licensed products that meet appropriate standards of safety, quality and efficacy to be available. Marketing authorisation applications have been submitted and interest in licensing continues.</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 197422 question first answered 06/05/2014 12:00:00 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

49357

registered interest
date	30/04/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether his Department has given consideration to licensing e-cigarettes as medicines.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	197422
answer	answer is ministerial correction date of answer 06/05/2014 answer text <p /> <p /> <p>On 14 March 2014, European Union member states formally adopted the revised Tobacco Products Directive, including the provisions for regulation of electronic cigarettes. Article 18 of the Directive will subject electronic cigarettes to consumer products legislation, with specific additional regulatory requirements unless they fall under the definition of a medicinal product.</p><p> </p><p>The Medicines and Healthcare products Regulatory Agency is continuing to focus on regulating medicinal nicotine containing products, including electronic cigarettes, to enable licensed products that meet appropriate standards of safety, quality and efficacy to be available. Marketing authorisation applications have been submitted and interest in licensing continues.</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 197421 question first answered 06/05/2014 12:00:00 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

49358

registered interest
date	30/04/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if his Department will put restrictions in place to prevent the promotion of e-cigarettes to people under the age of 16 years.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	197423
answer	answer is ministerial correction date of answer 06/05/2014 answer text <p>The revised Tobacco Products Directive (Directive 2014/40/EU) will prohibit the advertising of e-cigarettes marketed as consumer electronic products where there is a cross-border dimension, for example television, radio, newspapers and magazines. The Department will consult on the transposition of the Directive into United Kingdom law and seek views on the need for domestic provisions on advertising.</p><p> </p><p>It was not possible to achieve age of sale controls through the revised Directive so the Government has already moved quickly to take regulation-making powers for Ministers in England and Wales to prohibit the sale of e-cigarettes to under-18s, through the Children and Families Act. In England, we plan to bring this new law into effect within the current Parliament.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 06/05/2014 12:00:00 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile